GLP-3 R Phase 2: −28.7%143 Compounds · 5 Layers>98% HPLC All VialsFree Shipping $200+Third-Party Test ReportsResearch Use OnlyCAS Numbers VerifiedGHK-Cu: 4,000+ GenesGLP-3 R Phase 2: −28.7%143 Compounds · 5 Layers>98% HPLC All VialsFree Shipping $200+Third-Party Test ReportsResearch Use OnlyCAS Numbers VerifiedGHK-Cu: 4,000+ Genes
Guide8 min read2026-04-18

MGF: Mechano Growth Factor Research Overview

MGF is the IGF-1 splice variant muscle produces in response to mechanical loading. Here is why it operates on a different research timescale than standard IGF-1.

A Splice Variant, Not a Separate Gene

MGF (Mechano Growth Factor) is not a distinct gene product — it is the IGF-1Ec alternatively spliced variant of the IGF-1 gene, expressed preferentially by skeletal muscle in response to mechanical stress. Understanding MGF research requires understanding what distinguishes it from systemic IGF-1.

The research-grade peptide is available as MGF 2mg.

The Mechanical Loading Response

When skeletal muscle experiences mechanical loading, the IGF-1 gene undergoes alternative splicing that produces the IGF-1Ec (MGF) transcript. The protein product:

  • Has a 24-amino-acid C-terminal E-peptide extension
  • Acts locally at the site of production
  • Has a short half-life (minutes in circulation)
  • Produces biological effects distinct from mature IGF-1

The localized, short-acting nature is the defining research property.

Satellite Cell Activation

The primary MGF research target is the skeletal muscle satellite cell. MGF:

  1. Activates dormant satellite cells
  2. Promotes satellite cell proliferation
  3. Delays myogenic differentiation (keeping cells in the proliferative pool longer)
  4. Contributes to myofiber hypertrophy after injury or loading

The satellite cell pool is the regenerative reserve of skeletal muscle — research into its regulation is foundational to muscle biology.

Native MGF vs PEG-MGF

Two research peptides exist for MGF studies:

  • Native MGF: Short half-life, site-specific research
  • PEG-MGF: Polyethylene glycol-modified, extended systemic half-life

The choice depends on the research question:

Research GoalCompound
Local satellite cell responseNative MGF
Systemic IGF-1Ec signalingPEG-MGF
Site-of-injection pharmacologyNative MGF
Sustained circulating levelsPEG-MGF

Research Protocol Design

Native MGF's short half-life requires either:

  • Frequent site-specific administration
  • Acceptance that systemic effects are minimal
  • Combined protocols with other GH-axis compounds

Combining native MGF with GH-releasing compounds (CJC/Ipamorelin) creates a research protocol that stimulates both systemic GH and local IGF-1Ec expression — a more complete GH-axis engagement.

Sourcing

See MGF 2mg for the standard research vial.